P2 receptor antagonist trinitrophenyl-adenosine-triphosphate protects hippocampus from oxygen and glucose deprivation cell death

Journal of Pharmacology and Experimental Therapeutics

Volumn 323, Issue 1, 2007, Pages 70-77

  Cavaliere, Fabio ^a,b   Amadio, Susanna ^a   Dinkel, Klaus ^c   Reymann, Klaus G ^c,d   Volonté, Cinzia ^a,e  

^a IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^b Fundacion Inbiomed   (Spain)

^c LEIBNIZ INSTITUTE FOR NEUROBIOLOGY   (Germany)

^d FAN GmbH   (Germany)

^e CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE DERIVATIVE; GLUCOSE; OXYGEN; PURINE P2X RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; TRINITROPHENYL; TRINITROPHENYL ADENOSINE TRIPHOSPHATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN HYPOXIA; BRAIN ISCHEMIA; BRAIN REGION; CONTROLLED STUDY; DENTATE GYRUS; DOWN REGULATION; DRUG MECHANISM; GLUCOSE BRAIN LEVEL; GRANULAR CELL; HIPPOCAMPUS; LIGHT CHAIN; MOSSY FIBER; NERVE CELL NECROSIS; NEUROFILAMENT; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PYRAMIDAL NERVE CELL; RAT; RECEPTOR UPREGULATION;

ADENOSINE TRIPHOSPHATE; ANIMALS; BLOTTING, WESTERN; CELL DEATH; CULTURE MEDIA; ELECTROPHORESIS, POLYACRYLAMIDE GEL; GLUCOSE; HIPPOCAMPUS; NEURONS; ORGAN CULTURE TECHNIQUES; OXYGEN; RATS; RATS, WISTAR; RECEPTORS, PURINERGIC P2;

EID: 34548859862     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.119024     Document Type: Article

References (37)

1. Amadio S, D'Ambrosi N, Cavaliere F, Murra B, Sancesario G, Bernardi G, Burnstock G, and Volonté C (2002) P2 receptor modulation and cytotoxic function in cultured CNS neurons. Neuropharmacology 42:489-501.
2. Aschrafi A, Sadtler S, Niculescu C, Rettinger J, and Schmalzing G (2004) Trimeric architecture of homomeric P2X2 and heteromeric P2X12 receptor subtypes. J Mol Biol 342:333-343.
3. Brown SG, Townsend-Nicholson A, Jacobson KA, Burnstock G, and King BF (2002) Heteromultimeric P2X(1/2) receptors show a novel sensitivity to extracellular pH. J Pharmacol Exp Ther 300:673-680.
4. Burnstock G (1990) Overview. Purinergic mechanisms. Ann N Y Acad Sci 603:1-17.
5. Cavaliere F, Amadio S, Angelini DF, Sancesario G, Bernardi G, and Volonté C (2004a) Role of the metabotropic P2Y4 receptor during hypoglycemia: cross talk with the ionotropic NMDAR1 receptor. Exp Cell Res 300:149-158.
6. Cavaliere F, Amadio S, Sancesario G, Bernardi G, and Volonté C (2004b) Synaptic P2X7 and oxygen/glucose deprivation in organotypic hippocampal cultures. J Cereb Blood Flow Metab 24:392-398.
7. Cavaliere F, D'Ambrosi N, Ciotti MT, Mancino G, Sancesario G, Bernardi G, and Volonté C (2001) Glucose deprivation and mitochondrial dysfunction: neuroprotection by P2 receptor antagonists. Neurochem Int 38:189-197.
8. Cavaliere F, Dinkel K, and Reymann K (2005) Microglia response and P2 receptor participation in oxygen/glucose deprivation-induced cortical damage. Neuroscience 136:615-623.
9. Cavaliere F, Florenzano F, Amadio S, Fusco FR, Viscomi MT, D'Ambrosi N, Vacca F, Sancesario G, Bernardi G, Molinari M, et al. (2003) Up-regulation of P2X2, P2X4 receptor and ischemic cell death: prevention by P2 antagonists. Neuroscience 120:85-98.
10. Cavaliere F, Sancesario G, Bernardi G, and Volonté C (2002) Extracellular ATP and nerve growth factor intensify hypoglycemia-induced cell death in primary neurons: role of P2 and NGFRp75 receptors. J Neurochem 83:1129-1138.
11. Chechneva O, Dinkel K, Schrader D, and Reymann KG (2005) Identification and characterization of two neurogenic zones in interface organotypic hippocampal slice cultures. Neuroscience 136:343-355.
12. Chizh BA and Illes P (2001) P2X receptors and nociception. Pharmacol Rev 53:553-568.
13. Dirnagl U, Iadecola C, and Moskowitz MA (1999) Pathobiology of ischemic stroke: an integrated view. Trends Neurosci 22:391-397.
14. Fields RD and Burnstock G (2006) Purinergic signalling in neuron-glia interactions. Nat Rev Neurosci 7:423-436.
15. Franke H and Illes P (2006) Involvement of P2 receptors in the growth and survival of neurons in the CNS. Pharmacol. Ther 109:297-324
16. Gever JR, Cockayne DA, Dillon MP, Burnstock G, and Ford AP (2006) Pharmacology of P2X channels. Pflugers Arch 452:513-537.
17. Hachinski V (2002) Stroke: the next 30 years. Stroke 33:1-4.
18. Hillman KL, Doze VA, and Porter JE (2005) Functional characterization of the β-adrenergic receptor subtypes expressed by CA1 pyramidal cells in the rat hippocampus. J Pharmacol Exp Ther 314:561-567.
19. Illes P and Ribeiro JA (2004) Molecular physiology of P2 receptors in the central nervous system. Eur J Pharmacol 483:5-17.
20. Khakh BS, Burnstock G, Kennedy C, King BF, North RA, Seguela P, Voigt M, and Humphrey PP (2001) International union of pharmacology. XXIV. Current status of the nomenclature and properties of P2X receptors and their subunits. Pharmacol Rev 53:107-118.
21. Kucher BM and Neary JT (2005) Bi-functional effects of ATP/P2 receptor activation on tumor necrosis factor-alpha release in lipopolysaccharide- stimulated astrocytes. J Neurochem 92:525-535.
22. Kukley M, Barden JA, Steinhauser C, and Jabs R (2001) Distribution of P2X receptors on astrocytes in juvenile rat hippocampus. Glia 36:11-21.
23. Lewis CJ, Surprenant A, and Evans RJ (1998) 2′,3′-O-(2,4,6- trinitrophenyl) adenosine 5′-triphosphate (TNP-ATP)-a nanomolar affinity antagonist at rat mesenteric artery P2X receptor ion channels. Br J Pharmacol 124:1463-1466.
24. Melani A, Amadio S, Gianfriddo M, Vannucchi MG, Volonté C, Bernardi G, Pedata F, and Sancesario G (2006) P2X(7) receptor modulation on microglial cells and reduction of brain infarct caused by middle cerebral artery occlusion in rat. J Cereb Blood Flow Metab 26:974-982.
25. Neary JT and Kang Y (2005) Signaling from P2 nucleotide receptors to protein kinase cascades induced by CNS injury: implications for reactive gliosis and neurodegeneration. Mol Neurobiol 31:95-103.
26. Nicke A, Kerschensteiner D, and Soto F (2005) Biochemical and functional evidence for heteromeric assembly of P2X1 and P2X4 subunits. J Neurochem 92:925-933.
27. North RA (2002) Molecular physiology of P2X receptors. Physiol Rev 82:1013-1067.
28. Pozzo Miller LD, Mahanty NK, Connor JA, and Landis DM (1994) Spontaneous pyramidal cell death in organotypic slice cultures from rat hippocampus is prevented by glutamate receptor antagonists. Neuroscience 63:471-487.
29. Roberts JA, Vial C, Digby HR, Agboh KC, Wen H, Atterbury-Thomas A, and Evans RJ (2006) Molecular properties of P2X receptors. Pflugers Arch 452:486-500.
30. Rodrigues RJ, Almeida T, Richardson PJ, Oliveira CR, and Cunha RA (2005) Dual presynaptic control by ATP of glutamate release via facilitatory P2X1, P2X2/3, and P2X3 and inhibitory P2Y1, P2Y2, and/or P2Y4 receptors in the rat hippocampus. J Neurosci 25:6286-6295.
31. Shepherd GM and Harris KM (1998) Three-dimensional structure and composition of CA3-CA1 axons in rat hippocampal slices: implications for presynaptic connectivity and compartmentalization. J Neurosci 18:8300-8310.
32. Stoppini L, Buchs PA, and Muller D (1991) A simple method for organotypic cultures of nervous tissue. J Neurosci Methods 37:173-182.
33. 2/3 receptors. Mol Pharmacol 53:969-973.
34. Volonté C, Amadio S, Cavaliere F, D'Ambrosi N, Vacca F, and Bernardi G (2003) Extracellular ATP and neurodegeneration. Curr Drug Targets CNS Neurol Disord 2:403-412.
35. Volonté C, Amadio S, D'Ambrosi N, Colpi M, and Burnstock G (2006) P2 receptor web: complexity and fine-tuning. Pharmacol Ther 112:264-280.
36. Volonté C, Ciotti MT, D'Ambrosi N, Lockhart B, and Spedding M (1999) Neuroprotective effects of modulators of P2 receptors in primary culture of CNS neurones. Neuropharmacology 38:1335-1342.
37. Volonté C and Merlo D (1996) Selected P2 purinoceptor modulators prevent glutamate-evoked cytotoxicity in cultured cerebellar granule neurons. J Neurosci Res 45:183-193.